Physician profile
Michael Easton
NPI 1710019948
$1,214.54
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $249 · 2020: $57.01 · 2021: $198 · 2022: $689 · 2024: $22.09.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $22.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $22.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $145.22 | 2022 | |
| Janssen Pharmaceuticals, INC | $131.60 | 2019-2022 | |
| Harmony Biosciences LLC | $124.44 | 2022 | |
| Allergan, INC. | $111.48 | 2019 | |
| Lundbeck LLC | $96.70 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $87.16 | 2021-2022 | |
| Alkermes, INC. | $78.94 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $74.79 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $69.07 | 2020-2022 | |
| Neurocrine Biosciences, INC. | $60.21 | 2020-2022 | |
| Lilly USA, LLC | $51.61 | 2022 | |
| Neuronetics, INC. | $33.51 | 2022 | |
| Merck Sharp & Dohme LLC | $29.92 | 2022 | |
| Amgen INC. | $27.93 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $22.09 | 2024 | Opdivo |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.51 | 2021 | |
| Sage Therapeutics, LLC | $19.35 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $15.09 | 2020 | |
| Alfasigma USA, INC. | $13.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Easton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.